Ruben A. Mesa, MD, on Myeloproliferative Neoplasms: Managing PV and ET

2017 NCCN Hematologic Malignancies Congress
Tweet this page

Ruben A. Mesa, MD, of The University of Texas Health San Antonio Cancer Center, discusses the role of JAK2 inhibitors in treating polycythemia vera and essential thrombocythemia and how to develop individualized therapy based on risk stratification.

Advertisement

Advertisement



Advertisement